JANX Stock Overview
A clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Janux Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$45.49 |
52 Week High | US$65.60 |
52 Week Low | US$5.65 |
Beta | 3.87 |
1 Month Change | -6.57% |
3 Month Change | 246.19% |
1 Year Change | 221.94% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 80.87% |
Recent News & Updates
Recent updates
Janux Therapeutics: A Prime Target In Cancer Care's M&A Game
Apr 11Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024
Feb 27Companies Like Janux Therapeutics (NASDAQ:JANX) Are In A Position To Invest In Growth
Feb 24Is Janux Therapeutics, Inc. (NASDAQ:JANX) Trading At A 37% Discount?
Dec 29Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans
Nov 04We're Hopeful That Janux Therapeutics (NASDAQ:JANX) Will Use Its Cash Wisely
Jul 20A Look At The Intrinsic Value Of Janux Therapeutics, Inc. (NASDAQ:JANX)
May 23Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation
Feb 09We Think Janux Therapeutics (NASDAQ:JANX) Can Afford To Drive Business Growth
Oct 19Janux Therapeutics GAAP EPS of -$0.41, revenue of $2.37M
Aug 09We Think Janux Therapeutics (NASDAQ:JANX) Can Easily Afford To Drive Business Growth
Jun 05Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans
Feb 19Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation
Nov 03Shareholder Returns
JANX | US Biotechs | US Market | |
---|---|---|---|
7D | -5.1% | 0.7% | 1.2% |
1Y | 221.9% | 5.0% | 27.7% |
Return vs Industry: JANX exceeded the US Biotechs industry which returned 5.8% over the past year.
Return vs Market: JANX exceeded the US Market which returned 26% over the past year.
Price Volatility
JANX volatility | |
---|---|
JANX Average Weekly Movement | 65.6% |
Biotechs Industry Average Movement | 11.2% |
Market Average Movement | 5.9% |
10% most volatile stocks in US Market | 16.2% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: JANX's share price has been volatile over the past 3 months.
Volatility Over Time: JANX's weekly volatility has increased from 34% to 66% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2017 | 68 | David Campbell | www.januxrx.com |
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company’s clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products.
Janux Therapeutics, Inc. Fundamentals Summary
JANX fundamental statistics | |
---|---|
Market cap | US$2.49b |
Earnings (TTM) | -US$55.59m |
Revenue (TTM) | US$7.29m |
323.6x
P/S Ratio-42.4x
P/E RatioIs JANX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
JANX income statement (TTM) | |
---|---|
Revenue | US$7.29m |
Cost of Revenue | US$53.13m |
Gross Profit | -US$45.84m |
Other Expenses | US$9.75m |
Earnings | -US$55.59m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.07 |
Gross Margin | -629.07% |
Net Profit Margin | -762.92% |
Debt/Equity Ratio | 0% |
How did JANX perform over the long term?
See historical performance and comparison